Clinical characteristics of COVID-19 rebound after nirmatrelvir-ritonavir or molnupiravir therapy: A prospective cohort study.

Han, Jaijun; Bae, Seongman; Jung, Jiwon; Kim, Min Jae; Chong, Yong Pil; Lee, Sang-Oh; Choi, Sang-Ho; Kim, Yang Soo; Chang, Euijin; Kim, Sung-Han

Han, Jaijun; Bae, Seongman; Jung, Jiwon; Kim, Min Jae; Chong, Yong Pil; Lee, Sang-Oh; Choi, Sang-Ho; Kim, Yang Soo; Chang, Euijin; Kim, Sung-Han.

Affiliation

Han J; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Medicine (Baltimore) ; 102(39): e35094, 2023 Sep 29.

Article in En | MEDLINE | ID: mdl-37773854

Subject(s)

COVID-19; Ritonavir; Humans; Prospective Studies; Ritonavir/therapeutic use; COVID-19 Drug Treatment; Antiviral Agents/therapeutic use

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ritonavir / COVID-19 Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Medicine (Baltimore) Year: 2023 Document type: Article Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google